anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Application of lidocaine and prilocaine cream, 2.5%/2.5% to larger areas or for longer times than those recommended could result in sufficient absorption of lidocaine and prilocaine resulting in serious adverse effects (see Individualization of Dose).

Patients treated with class III anti-arrhythmic drugs (e.g., amiodarone, bretylium, sotalol, dofetilide) should be under close surveillance and ECG monitoring considered, because cardiac effects may be additive.

Studies in laboratory animals (guinea pigs) have shown that lidocaine and prilocaine cream, 2.5%/2.5% has an ototoxic effect when instilled into the middle ear. In these same studies, animals exposed to lidocaine and prilocaine cream, 2.5%/2.5% only in the external auditory canal, showed no abnormality. Lidocaine and prilocaine cream, 2.5%/2.5% should not be used in any clinical situation when its penetration or migration beyond the tympanic membrane into the middle ear is possible.

Methemoglobinemia: Cases of methemoglobinemia have been reported in association with local anesthetic use. Although all patients are at risk for methemoglobinemia, patients with glucose- 6-phosphate dehydrogenase deficiency, congenital or idiopathic methemoglobinemia, cardiac or pulmonary compromise, infants under 6 months of age, and concurrent exposure to oxidizing agents or their metabolites are more susceptible to developing clinical manifestations of the condition. If local anesthetics must be used in these patients, close monitoring for symptoms and signs of methemoglobinemia is recommended. 

Signs of methemoglobinemia may occur immediately or may be delayed some hours after exposure, and are characterized by a cyanotic skin discoloration and/or abnormal coloration of the blood. Methemoglobin levels may continue to rise; therefore, immediate treatment is required to avert more serious central nervous system and cardiovascular adverse effects, including seizures, coma, arrhythmias, and death. Discontinue lidocaine and prilocaine cream, 2.5%/2.5% and any other oxidizing agents. Depending on the severity of the signs and symptoms, patients may respond to supportive care, i.e., oxygen therapy, hydration. A more severe clinical presentation may require treatment with methylene blue, exchange transfusion, or hyperbaric oxygen.
Group receiving CSB repackaged into 2kg packages with messages on package on how to prepare. Only in Phase II.
Life-threatening thrombotic events and neurological symptoms are prevalent in COVID-19 and are persistent in patients with long COVID experiencing post-acute sequelae of SARS-CoV-2 infection1-4. Despite the clinical evidence1,5-7, the underlying mechanisms of coagulopathy in COVID-19 and its consequences in inflammation and neuropathology remain poorly understood and treatment options are insufficient. Fibrinogen, the central structural component of blood clots, is abundantly deposited in the lungs and brains of patients with COVID-19, correlates with disease severity and is a predictive biomarker for post-COVID-19 cognitive deficits1,5,8-10. Here we show that fibrin binds to the SARS-CoV-2 spike protein, forming proinflammatory blood clots that drive systemic thromboinflammation and neuropathology in COVID-19. Fibrin, acting through its inflammatory domain, is required for oxidative stress and macrophage activation in the lungs, whereas it suppresses natural killer cells, after SARS-CoV-2 infection. Fibrin promotes neuroinflammation and neuronal loss after infection, as well as innate immune activation in the brain and lungs independently of active infection. A monoclonal antibody targeting the inflammatory fibrin domain provides protection from microglial activation and neuronal injury, as well as from thromboinflammation in the lung after infection. Thus, fibrin drives inflammation and neuropathology in SARS-CoV-2 infection, and fibrin-targeting immunotherapy may represent a therapeutic intervention for patients with acute COVID-19 and long COVID.
The present invention relates to a three-dimensional biocompatible matrix comprising a three-dimensional scaffold made of a polymeric agent, and comprising at least one further component. The present invention also relates to a composition comprising such three-dimensional biocompatible matrix. Furthermore, the present invention also relates to uses of such three-dimensional biocompatible matrix and/or composition. In particular, the present invention also relates to such three-dimensional biocompatible matrix and/or composition for use in methods of wound treatment or management. Moreover, the present invention also relates to a method for producing a three-dimensional biocompatible matrix according to the present invention. Furthermore, the present invention relates to an ink composition for three-dimensional ( 3 D) printing and its uses in producing a three-dimensional biocompatible matrix according to the present invention.
This is an exploratory prospective study (a study in which the patients are identified and then followed forward in time for the outcome of the study). The study will consist of two phases: a screening phase (Day 1) and an assessment phase (Day 2 to Day 7). During screening phase, in pediatric patients hospitalized with LRTI and from whom the informed consent form was obtained, diagnosis of RSV infection will be performed within 24h from the hospital admission, using a SOFIA POC test on nasal specimens. During the assessment phase the collection of nasal specimens will be done daily for a maximum of 6 days (Day 2 to Day 7 of hospitalization) or until patient discharge from hospital. Approximately 50 patients will be enrolled in this study. The total duration of the study for each participant will be approximately 7 days. The study duration will extend during 1-3 RSV epidemic seasons, or until the targeted number of 50 RSV hospitalized children have completed the study.
Patients will be managed by primary care provider with a stepped care approach supported by current practice guidelines. Initial management will include education and re-assurance for the first 4 weeks following the primary care visit. Patients in will be recommended to follow-up with their primary care provider if unsatisfied with their progress after 4 weeks. At that time decisions on further treatments and/or referrals will be made by the primary care provider in consultation with the patient consistent with usual care.
The invention comprises a white, solid water-soluble, heat-stable, non-dialysable acidic polysaccharide of very high molecular weight and salts thereof, which contains, in free acid form, only the elements carbon, hydrogen, oxygen and nitrogen and is characterized by the following analytical data: [a ]23D=about - 79.4 degrees in water when dried to constant weight at 50 DEG  C.; in free acid form shows infra-red absorption maxima at approximately 2.95, 3.22, 3.33, 3.37, 5.73, 6.00, 6.43, 6.96, 7.24, 7.61, 8.04, 8.77, 9.49, 10.83, 11.13 and 11.52 microns in a potassium bromide disc; gives negative Molisch and anthrone tests; on hydrolysis gives a positive Elson-Morgan test; by heating with diphenylamine in acetic acid-sulphuric acid mixture gives a blue solution showing an absorption maximum at 575 millimicrons; by heating in 79% sulphuric acid gives a solution having an ultra-violet absorption maximum at 290 millimicrons; by heating in acetic acid containing 10% sulphuric acid gives a solution having absorption maxima at 283, 410 and 470 millimicrons; moves towards the anode in electrophoresis at pH values of 4 and above and is detectable as a pink spot when sprayed with para-anisidine in butanol and sulphuric acid; and has a viscosity of about 0.0151 poises at 23 DEG  C. (0.3% in water). The polysaccharide is prepared by heating, with dilute acetic acid, the phenol-insoluble, water-insoluble solid residue resulting from the extraction of strains of Staphylococcus aureus with phenol and an aqueous solvent.  Preferably the solid is heated with 0.1 N acetic acid for 5 minutes under pressure at 121 DEG  C.  The aqueous phase, containing the polysaccharide is then separated by e.g. centrifugation.  The free-acid polysaccharide may be isolated by dialysis and freeze-drying and purified by means of chromatography or complex-formation.  The free acid may be converted to e.g. sodium, potassium, calcium, magnesium, ammonium and amine salts by titration with appropriate bases. Aqueous solutions of the polysaccharide or salts thereof are used as vaccines for immunization against staphylococcal infections (see Division A5).ALSO:Vaccines for immunization against staphylococcal infection comprise aqueous solutions of a nitrogen-containing polysaccharide obtained by acetic acid hydrolysis of the phenol-insoluble, water-insoluble solid residue resulting after extraction of strains of staphylococcus aureus with phenol and water (Division C3).  The vaccine may be rendered isotonic, e.g. by addition of sodium chloride, and may be sterilized by means of heat, ultraviolet irradiation or by addition of preservatives, e.g. thimerosal, benzethonium chloride or phenol.
A method, computing device and computer program product are provided to define a level of assurance in one or more links between patient records that relate to the same person based upon external information. In the context of a method, one or more links are identified between a patient record associated with a person and pre-existing patient records. Each pre-existing patient record has a plurality of demographic attributes associated with a patient. The method identifies one or more links based upon an analysis of the demographic attributes of the person and the respective patients associated with the pre-existing patient records. The method receives external information regarding a relationship between the person and the respective patients associated with the pre-existing patient records or regarding confirmation of an identity of the person. The method also defines a level of assurance in the respective one or more links based upon the external information.
Celexa® (citalopram HBr) is an orally administered selective serotonin reuptake inhibitor (SSRI) with a chemical structure unrelated to that of other SSRIs or of tricyclic, tetracyclic, or other available antidepressant agents. Citalopram HBr is a racemic bicyclic phthalane derivative designated (±)-1-(3-dimethylaminopropyl)-1-(4-fluorophenyl)-1,3-dihydroisobenzofuran-5-carbonitrile, HBr with the following structural formula:

The molecular formula is C20H22BrFN2O and its molecular weight is 405.35.

Citalopram HBr occurs as a fine, white to off-white powder. Citalopram HBr is sparingly soluble in water and soluble in ethanol.

Celexa (citalopram hydrobromide) is available as tablets or as an oral solution.

Celexa 10 mg tablets are film-coated, oval tablets containing citalopram HBr in strengths equivalent to 10 mg citalopram base. Celexa 20 mg and 40 mg tablets are film-coated, oval, scored tablets containing citalopram HBr in strengths equivalent to 20 mg or 40 mg citalopram base. The tablets also contain the following inactive ingredients: copolyvidone, corn starch, crosscarmellose sodium, glycerin, lactose monohydrate, magnesium stearate, hypromellose, microcrystalline cellulose, polyethylene glycol, and titanium dioxide. Iron oxides are used as coloring agents in the beige (10 mg) and pink (20 mg) tablets.

Celexa oral solution contains citalopram HBr equivalent to 2 mg/mL citalopram base. It also contains the following inactive ingredients: sorbitol, purified water, propylene glycol, methylparaben, natural peppermint flavor, and propylparaben.
A system, a method and non-transitory computer readable medium are provided. The method includes receiving a message from a gateway. The message includes an identification parameter associated with the gateway that received a ping from a beacon. The message also includes a beacon identifier of the beacon that transmitted the ping, the ping included the beacon identifier. The message further includes a derived signal strength parameter that indicates a proximity of the beacon to the gateway when the beacon transmitted the ping. The method also includes acquiring an outcome associated with medical-care that is provided by a medical provider to a patient. The method further includes identifying a cost associated with the medical-care provided by the medical provider based in part on the received message. The method additionally includes generating a value score that relates the identified cost of providing the medical-care to the patient, to the acquired outcome.
Subjects who randomize to this arm will receive larger diameter bare platinum coils for treatment of their cerebral aneurysm. Subjects in this arm could receive a combination of the following protocol approved intracranial coils depending on the phase: Target XL 360 Standard, Target XL 360 Soft, Target XL 360 Helical, GDC-18 360 Standard, GDC-18 3D, GDC-18 2D, GDC-18 Soft, and/or 0.014-0.0155 inch diameter bare platinum intracranial coils.
The invention discloses a microcapsule with chemotherapeutic drugs and thermotherapy sensitizers and a preparation method thereof. The diameter of the microcapsule is 0.5 to 250 μm, and the thickness of the shell of the microcapsule is 0.05 to 30 μm. The microcapsule with the chemotherapeutics and the thermotherapy sensitizer comprises a shell and a core material, wherein the shell is made of carboxymethyl chitosan, the core material is wrapped in the shell, the core material comprises the photothermal sensitizer and the chemotherapeutics, and the outer surface of the shell is coupled with targeting molecules. The microcapsule of the invention is prepared according to the following steps: emulsifying, interfacial polymerization, folic acid coupling and washing to obtain the material for wrapping photothermal heating and tumor embolization. The microcapsule prepared by the invention has the advantages of simple process, good repeatability, high production efficiency and easy realization of large-scale production. The microcapsule prepared by the invention has controllable granularity, size and thickness. The shell material contains a large amount of amino groups, and can endow functions such as drug controlled release, antibody coupling and the like. The microcapsule is a carboxymethyl chitosan microcapsule carrier with the advantages of photo-thermal sensitization, chemotherapy drug sustained and controlled release, targeting and good biocompatibility, and has good application prospect when being used as an embolic agent in breast cancer treatment.
Participants will be on each diet for one week prior to collection of laboratory samples. Participants will be on their normal diet on weeks 1 and 3, on the high fat diet on week 2, and low fat diet on week 4.
PURPOSE: A composition containing an extract of Castanea crenata Sieb. et Zucc. producing a human estrogen receptor-binding material as an effective component is provided. Because the composition has androgenicity, it can be used as a prophylactic and therapeutic agent for androgen deficiency and prostate cancer as well as a health food composition. CONSTITUTION: The pharmaceutical composition contains 0.1 to 50% by weight of a Castanea crenata extract, in which the extract is administered at daily doses of 0.001 to 100mg/kg through an oral, transdermal, subcutaneous, intravenous or muscular pathway. For example, 100g Castanea crenata Sieb. et Zucc. is added to 2L ethanol, flowed backward while heating at 90deg.C for 3hr, filtered and then concentrated under reduced pressure.
The patient's preoperative CT and MR imaging data were fused with a neuronavigation system to avoid important functional areas and select the closest point of the hematoma to the cortex as the location point. Routine craniotomy was performed with a 2\*3 cm bone window, the puncture direction was repositioned by neuronavigation, the sheath was placed at the center of the hematoma, the core was removed, the endoscope was gradually aspirated, and the bleeding was stopped with electrocoagulation if there was considerable active bleeding. A drainage tube was placed, the bone flap was reset after surgery, and the scalp was sutured.
The treatment of severe acute pancreatitis (SAP), with high mortality rates, poses a significant clinical challenge. Investigating the pathological changes associated with SAP using animal models can aid in identifying potential therapeutic targets and exploring novel treatment approaches. Previous studies primarily induced pancreatic injury through retrograde bile duct injection of sodium taviaurocholate, but the impact of surgical damage on the quality of the animal model remains unclear. In this study, we employed various frequencies of intraperitoneal Caerulein injections combined with different doses of LPS to induce pancreatic injury in C57BL/6J mice and compared the extent of injury across five intraperitoneal injection protocols. Regarding inducing acute pancreatitis in mice, an intraperitoneal injection protocol is proposed that results in a mortality rate as high as 80% within 5 days. Specifically, mice received ten daily intraperitoneal injections of Caerulein (50 µg/kg), followed by an injection of LPS (15 mg/kg) one hour after the last Caerulein administration. By adjusting the frequency and dosage of injected medications, one can manipulate the severity of pancreatic injury effectively. This model exhibits strong controllability and has a short replication cycle, making it feasible for completion by a single researcher without requiring expensive equipment. It conveniently and accurately simulates key disease characteristics observed in human SAP while demonstrating a high degree of reproducibility.
<P>PROBLEM TO BE SOLVED: To provide a method for screening a remedy for rheumatoid arthritis and to provide a medicinal composition for treatment of rheumatoid arthritis based on a new action mechanism.  <P>SOLUTION: The inventors found that DGPP1S protein, DGPP1L protein, DGPP2S protein and DGPP2L protein have phosphatase activity and the polypeptide expresses and enhances in vascular endothelium of synovial membrane tissue of human RA patient. Further, the inventors found that inhibition of expression of DGPP1S protein and DGPP1L protein brings about inhibition of vascular endothelial growth. The present invention established and provided a method of screening a remedy for rheumatoid arthritis by selecting an inhibitor for DGPP1S protein and DGPP1L protein and/or an inhibitor for DGPP2S protein and DGPP2L protein, because it is thought that vascularization in synovial membrane tissue involves progress of morbid state. The present invention provided, further, a remedy for rheumatoid arthritis comprising the above inhibitor as the active ingredient.  <P>COPYRIGHT: (C)2007,JPO&INPIT
Chronic back pain patients will titrate onto sustained release oral morphine for 30 days, and then will be randomized to take either ondansetron 8 mg or matching placebo thirty minutes prior to naloxone-induced withdrawal in clinic (Naloxone 0.4 mg/70 kg; if deemed necessary by the clinician to induce withdrawal, a second naloxone dose may be administered at 0.8 mg/70 kg). Participants will return to their titrated morphine dose for one week and then return for the opposite pre-treatment followed by naloxone-induced withdrawal in clinic. Participants will then taper back to their original dose of morphine for one week.
A compact single use applicator is disclosed having a dry medication (e.g, a dehydrated or lyophilized astringent disinfectant that is adapted to treat ache and has been reduced to a powder) stored in a flexible mixing chamber. Liquid diluents are stored in first and second flexible chambers. Fluid communication between the diluents in the first and second chambers and the dry medication in the mixing chamber is blocked by normally closed, pressure activated fluid paths. By compressing the first and second chambers, corresponding hydraulic pressures are generated in the diluents thereof which force open the pressure activated paths. Accordingly, the diluents in the first and second chambers are introduced under pressure to the dry medication in the mixing chamber to rehydrate and reactivate the medication. The reconstituted multi-constituent liquid medication is then supplied from the mixing chamber to a dispensing chamber via another normally closed pressure activated fluid path. The liquid medication is absorbed by an applicator pad, or the like, that is surrounded by the dispensing chamber, whereby the medication can be applied via an opening through the dispensing chamber to a relatively wide tissue area as a topical treatment for ache or other skin disorder.
BACKGROUND: The emergence of non-communicable diseases (NCDs) has been well documented in recent literature which constitute a significant global burden of disease. Qatar which has a significantly high prevalence of NCDs with early on set. Epidemiological and health service utilization information plays a central role in facilitating informed decision making and application of the fundamental principles of PHC in planning and delivery of healthcare with aim to prevent and control NCDs. To enable this, the Department of Clinical Research at Primary Health Care Corporation (PHCC), Qatar's publicly funded and largest primary care provider designed the Health Assessment Linking Trends in Health Status, Risks, and Healthcare Utilization (HEALTHSIGHT) study. This paper describes the HEALTHSIGHT study protocol.
METHODS: The proposed study will use a cross sectional study design involving a random sample of participants enrolled across all 31 PHCC health centers. Individuals aged 18 and above years old registered with PHCC and hold a valid health card and contact information on PHCC's electronic medical records (EMR) will be eligible for inclusion. A stratified random sample not proportional to size sampling technique will be employed to obtain a representative sample size of the PHCC population (N = 6000). Participants will be scheduled for an appointment at a PHCC health centre where a data collector will obtain informed consent, collect vital sign information and administer a questionnaire. A phlebotomist will collect a blood sample. Health service utilization data will be extracted from PHCC's EMR.
DISCUSSION: Epidemiological and health service utilization information is essential to plan and monitor primary care and public health services. The HEALTHSIGHT study, with the help of a randomly selected representative sample from Qatar's primary healthcare settings, provides a unique opportunity to capture this information. This study design will closely represent a real-world understanding of the health risk, status and utilisation and is likely to provide important data to guide primary care planning and delivery in Qatar. The proposed protocol provides an example of a robust nationwide study that be undertaken in short duration using limited resource which can be undertaken in other similar settings.